Literature DB >> 31980337

The etiology of rheumatoid arthritis.

Hans Ulrich Scherer1, Thomas Häupl2, Gerd R Burmester2.   

Abstract

Rheumatoid arthritis is a heterogeneous disease, which can be, based on data combining genetic risk factors and autoantibodies, sub-classified into ACPA-positive and -negative RA. Presence of ACPA and RF as well as rising CRP-levels in some patients years before onset of clinical symptoms indicate that relevant immune responses for RA development are initiated very early. ACPA are highly specific for RA, whereas RF can also be found among healthy (elderly) individuals and patients with other autoimmune diseases or infection. The most important genetic risk factor for RA development, the shared epitope alleles, resides in the MHC class II region. Shared epitope alleles, however, only predispose to the development of ACPA-positive RA. Smoking is thus far the most important environmental risk factor associated with the development of RA. Studies on synovitis have shown the importance not only of adaptive but also of innate immune responses. In summary of the various results from immunological changes in blood and synovial tissue, the extension of the immune response from a diffuse myeloid to a lympho-myeloid inflammation appears to be associated with a more successful therapeutic response to biologics. With respect to advances in synovitis research, new targets for treatment against pathological subsets of immune cells or fibroblasts are already on the horizon. However, alternative strategies involving the microbiome may play an important role as well and research in this field is growing rapidly.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  ACPA; AMPA; Etiology; Microbiome; Pathogenesis; Rheumatoid arthritis; Rheumatoid factor; Synovitis

Mesh:

Substances:

Year:  2020        PMID: 31980337     DOI: 10.1016/j.jaut.2019.102400

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  71 in total

1.  Repurposing monoamine oxidase inhibitors (MAOI) for the treatment of rheumatoid arthritis possibly through modulating reactive oxidative stress mediated inflammatory cytokines.

Authors:  Debjeet Sur; Arpan Dutta; Chaitali Mondal; Apurba Banerjee; Pallab Kanti Haldar; Himangshu Sekhar Maji; Asis Bala
Journal:  Inflammopharmacology       Date:  2022-03-10       Impact factor: 4.473

2.  Potential role of embelin in the prevention of Freund's adjuvant induced inflammation and ROS.

Authors:  H M Kumaraswamy; V Krishna; R Sharath; N D Satyanarayan; P Meghana; R Sandeep Kumar Jain; N Prashanth; H Raja Naika
Journal:  3 Biotech       Date:  2021-12-08       Impact factor: 2.406

3.  Osteoporosis in patients with rheumatoid arthritis is associated with serum immune regulatory cellular factors.

Authors:  Jianjun Qiu; Chunde Lu; Lei Zhang; Xu Zhou; Hanlin Zou
Journal:  Clin Rheumatol       Date:  2022-06-07       Impact factor: 3.650

Review 4.  Systematic Review: Targeted Molecular Imaging of Angiogenesis and Its Mediators in Rheumatoid Arthritis.

Authors:  Fatemeh Khodadust; Aiarpi Ezdoglian; Maarten M Steinz; Judy R van Beijnum; Gerben J C Zwezerijnen; Gerrit Jansen; Sander W Tas; Conny J van der Laken
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

Review 5.  Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes.

Authors:  Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

6.  The Outcome of Stem Cell-Based Therapies on the Immune Responses in Rheumatoid Arthritis.

Authors:  Peyvand Parhizkar Roudsari; Sepideh Alavi-Moghadam; Mostafa Rezaei-Tavirani; Parisa Goodarzi; Akram Tayanloo-Beik; Forough Azam Sayahpour; Bagher Larijani; Babak Arjmand
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Micronutrients: Essential Treatment for Inflammatory Arthritis?

Authors:  Marina Bañuls-Mirete; Alexis Ogdie; Monica Guma
Journal:  Curr Rheumatol Rep       Date:  2020-10-26       Impact factor: 4.592

Review 8.  Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response.

Authors:  Dmitry S Mikhaylenko; Marina V Nemtsova; Irina V Bure; Ekaterina B Kuznetsova; Ekaterina A Alekseeva; Vadim V Tarasov; Alexander N Lukashev; Marina I Beloukhova; Andrei A Deviatkin; Andrey A Zamyatnin
Journal:  Int J Mol Sci       Date:  2020-07-11       Impact factor: 5.923

9.  Identification of Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking.

Authors:  Liang Liang Bai; Hao Chen; Peng Zhou; Jun Yu
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

10.  Dysregulated microRNA expression in rheumatoid arthritis families-a comparison between rheumatoid arthritis patients, their first-degree relatives, and healthy controls.

Authors:  Emma Renman; Mikael Brink; Lisbeth Ärlestig; Solbritt Rantapää-Dahlqvist; Kristina Lejon
Journal:  Clin Rheumatol       Date:  2020-11-18       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.